[go: up one dir, main page]

WO1998031354A3 - Use of 5-HT2b agonists or potentiators in CNS disorders - Google Patents

Use of 5-HT2b agonists or potentiators in CNS disorders Download PDF

Info

Publication number
WO1998031354A3
WO1998031354A3 PCT/EP1998/000380 EP9800380W WO9831354A3 WO 1998031354 A3 WO1998031354 A3 WO 1998031354A3 EP 9800380 W EP9800380 W EP 9800380W WO 9831354 A3 WO9831354 A3 WO 9831354A3
Authority
WO
WIPO (PCT)
Prior art keywords
potentiators
cns disorders
ht2b
agonists
ht2b agonists
Prior art date
Application number
PCT/EP1998/000380
Other languages
French (fr)
Other versions
WO1998031354A2 (en
Inventor
Guy Anthony Kennett
Original Assignee
Smithkline Beecham Plc
Guy Anthony Kennett
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Plc, Guy Anthony Kennett filed Critical Smithkline Beecham Plc
Publication of WO1998031354A2 publication Critical patent/WO1998031354A2/en
Publication of WO1998031354A3 publication Critical patent/WO1998031354A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4525—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

The present invention discloses the use of 5-HT2B agonists or positive allosteric modulators (enhancers) such as paroxetine or BW-723C86 in the treatment of various CNS, affective, behavioral, migraine or feeding disorders, and in particular in depression.
PCT/EP1998/000380 1997-01-17 1998-01-13 Use of 5-ht2b agonists or potentiators in cns disorders WO1998031354A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB9700899.9 1997-01-17
GBGB9700899.9A GB9700899D0 (en) 1997-01-17 1997-01-17 Novel treatment

Publications (2)

Publication Number Publication Date
WO1998031354A2 WO1998031354A2 (en) 1998-07-23
WO1998031354A3 true WO1998031354A3 (en) 1998-09-17

Family

ID=10806125

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP1998/000380 WO1998031354A2 (en) 1997-01-17 1998-01-13 Use of 5-ht2b agonists or potentiators in cns disorders

Country Status (2)

Country Link
GB (1) GB9700899D0 (en)
WO (1) WO1998031354A2 (en)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6956036B1 (en) 2000-03-17 2005-10-18 Alcon, Inc. 6-hydroxy-indazole derivatives for treating glaucoma
US7005443B1 (en) 2000-03-17 2006-02-28 Alcon, Inc. 5-Hydroxy indazole derivatives for treating glaucoma
US7012090B1 (en) 2000-03-17 2006-03-14 Alcon, Inc. Pyranoindoles for treating glaucoma
US8618288B2 (en) 2003-09-17 2013-12-31 Janssen Pharmaceutica Nv Pyrimidine compounds as serotonin receptor modulators
US8883808B2 (en) 2005-08-04 2014-11-11 Janssen Pharmaceutica N.V. Combination of 5-HT7 receptor antagonist and serotonin reuptake inhibitor therapy

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TR200100754T2 (en) 1998-09-18 2001-10-22 Alcon Laboratories, Inc. Serotonergic 5HT2 for treating glaucoma.
WO2001070705A1 (en) 2000-03-17 2001-09-27 Alcon, Inc. 2-acylaminobenzimidazole derivatives for treating glaucoma
WO2001070686A1 (en) * 2000-03-17 2001-09-27 Alcon, Inc. 5-hydroxy indole derivatives for treating glaucoma
US6806285B1 (en) 2000-03-17 2004-10-19 Alcon, Inc. 5-Hydroxyl indole derivatives for treating glaucoma
CN100384417C (en) 2001-06-01 2008-04-30 艾尔科公司 Pyranoindazoles and use thereof for preparing medicament for treating glaucoma
CA2447156A1 (en) 2001-06-01 2002-12-12 Alcon, Inc. Novel fused indazoles and indoles and their use for the treatment of glaucoma
BR0210238A (en) 2001-06-01 2004-07-20 Alcon Inc New Aryl-Amino-Propane Analogs and Their Use for the Treatment of Glaucoma
TW593302B (en) 2001-12-20 2004-06-21 Alcon Inc Novel benzodifuranimidazoline and benzofuranimidazoline derivatives and their use for the treatment of glaucoma
MXPA05006277A (en) 2002-12-13 2005-09-08 Alcon Inc Novel benzopyran analogs and their use for the treatment of glaucoma.
WO2005053688A1 (en) 2003-11-26 2005-06-16 Alcon, Inc. Substituted furo[2,3-g] indazoles for the treatment of glaucoma
AR046890A1 (en) 2003-12-15 2005-12-28 Alcon Inc [1,4] OXAZINO [2,3-G] SUBSTITUTED INDAZOLS FOR THE TREATMENT OF GLAUCOMA.
US7129257B1 (en) 2003-12-15 2006-10-31 Alcon, Inc. Pyrazolo[3,4- e]benzoxazoles for the treatment of glaucoma
US7338972B1 (en) 2003-12-15 2008-03-04 Alcon, Inc. Substituted 1-alkylamino-1H-indazoles for the treatment of glaucoma
WO2006062839A1 (en) 2004-12-08 2006-06-15 Alcon, Inc. Use of dioxindoindazoles and dioxoloindazoles for treating glaucoma

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994025012A2 (en) * 1993-04-28 1994-11-10 Smithkline Beecham Plc Medicaments for treatment of migraine, epilepsy and feeding disorders
WO1996029074A1 (en) * 1995-03-22 1996-09-26 Eli Lilly And Company Methods of treating or preventing pain or nociception

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994025012A2 (en) * 1993-04-28 1994-11-10 Smithkline Beecham Plc Medicaments for treatment of migraine, epilepsy and feeding disorders
WO1996029074A1 (en) * 1995-03-22 1996-09-26 Eli Lilly And Company Methods of treating or preventing pain or nociception

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
AINSWORTH K ET AL: "Is #BW# #723C86#-induced hyperphagia an in vivo model of rat central 5-HT-2B receptor function?", BRITISH JOURNAL OF PHARMACOLOGY, 117 (PROC. SUPPL.). 1996. 178P., XP002069367 *
DUXON ET AL.: "Activation of 5HT-2B receptors in the medial amygdala causes anxiolysis in the social interaction test in the rat", NEUROPHARMACOLOGY, vol. 36, no. 4-5, April 1997 (1997-04-01) - May 1997 (1997-05-01), pages 601 - 608, XP002069368 *
KENNETT ET AL: "Effects o the 5-HT2B receptor agonist, BW 723C86, on three rat models of anxiety", BR. J. PHARMACOL., vol. 117, no. 7, April 1996 (1996-04-01), pages 1443 - 1448, XP002069364 *
KENNETT G A ET AL: "Does chronic administration of paroxetine or the 5-HT-2B receptor agonist, #BW# #723C86#, affect rat 5-HT-2B receptor function?", SOCIETY FOR NEUROSCIENCE ABSTRACTS, 22 (1-3). 1996. 1778., XP002069366 *
KENNETT GA ET AL: "Effect of chronic administration of selective 5-hydroxytryptamine and noradrenaline uptake inhibitors on a putative index of 5-HT2C/#2B# #receptor# function.", NEUROPHARMACOLOGY, DEC 1994, 33 (12) P1581-8, ENGLAND, XP002069365 *

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6956036B1 (en) 2000-03-17 2005-10-18 Alcon, Inc. 6-hydroxy-indazole derivatives for treating glaucoma
US7005443B1 (en) 2000-03-17 2006-02-28 Alcon, Inc. 5-Hydroxy indazole derivatives for treating glaucoma
US7012090B1 (en) 2000-03-17 2006-03-14 Alcon, Inc. Pyranoindoles for treating glaucoma
US8618288B2 (en) 2003-09-17 2013-12-31 Janssen Pharmaceutica Nv Pyrimidine compounds as serotonin receptor modulators
US8883808B2 (en) 2005-08-04 2014-11-11 Janssen Pharmaceutica N.V. Combination of 5-HT7 receptor antagonist and serotonin reuptake inhibitor therapy

Also Published As

Publication number Publication date
GB9700899D0 (en) 1997-03-05
WO1998031354A2 (en) 1998-07-23

Similar Documents

Publication Publication Date Title
WO1998031354A3 (en) Use of 5-HT2b agonists or potentiators in CNS disorders
WO2000043032A3 (en) Baff, inhibitors thereof and their use in the modulation of b-cell response
IL158867A0 (en) Ostepontin and agonists thereof in treatment and/or prevention of neurological diseases
DE69626660D1 (en) 2-alkylpyrrolidine
WO2001079460A3 (en) Polypeptides having haloperoxidase activity
AU2002343557A1 (en) Substituted aryl 1,4-pyrazine derivatives
WO2004047838A3 (en) Pharmaceutical composition comprising beta-3-adrenoceptor agonists and antimuscarinic agents
AU2002339691A1 (en) Agonists and antagonists of prolixin for the treatment of metabolic disorders
CA2257010A1 (en) Methods and compositions for the treatment and prevention of tumors, tumor-related disorders and cachexia
AU1753699A (en) Application of vasopressin antagonists for treating disturbances or illnesses ofthe inner ear
YU13301A (en) Muscarinic agonists and antagonists
WO2002039997A3 (en) Ace-2 modulating compounds and use thereof
WO2001015677A3 (en) Use of 5-ht1b/1d agonists to treat otic pain
IL144199A0 (en) Novel bretylium compositions and kits, and their use in preventing and treating cardiovascular conditions
WO2004037168A3 (en) Treatment of pancreatitis with amylin
IL135634A0 (en) 5-htif agonists
AU3630297A (en) Galanin
WO2002003684A3 (en) Combination for treating psychoses, comprising an antipsychotic and a muscarinic agonist
WO1999041373A3 (en) Human transport-associated molecules
WO2000042201A3 (en) Human peptidases
WO2004112729A8 (en) Dual function compounds and uses thereof
WO2003059332A3 (en) Use of an anti-microtubule agent for the treatment of uveitis
WO2004016604A3 (en) Azabicyclic compounds are central nervous system active agents
TR200101476T2 (en) The use of N-substituted azabicycloacane derivatives in the treatment of central nervous system disorders
GB0102408D0 (en) Chemical compounds

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): CA JP US

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: JP

Ref document number: 1998533697

Format of ref document f/p: F

122 Ep: pct application non-entry in european phase